Lysergide

Lysergide

SCHEMBL24449764

CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 13/20 1.00
▸ DRD3 P35462 4/20 1.00
▸ HTR2C P28335 3/20 1.00
▸ ADRB1 P08588 3/20 1.00
▸ HTR1A P08908 3/20 1.00
▸ DRD2 P14416 3/20 1.00
▸ DRD4 P21917 3/20 1.00
▸ HTR2B P41595 3/20 1.00
▸ HTR6 P50406 3/20 1.00
▸ ADRB2 P07550 2/20 1.00
▸ HRH1 P35367 2/20 1.00
▸ DRD5 P21918 1/20 1.00
▸ HTR1D P28221 1/20 1.00
▸ HTR1E P28566 1/20 1.00
▸ HTR7 P34969 1/20 1.00
▸ HTR5A P47898 1/20 1.00
▸ CYP2D6 P10635 3/20 0.72
▸ MEN1 O00255 3/20 0.72
▸ KMT2A Q03164 3/20 0.72
▸ ALDH1A1 P00352 2/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lysergide SCHEMBL30416462 1.00 HTR2A (1.00) HTR2ADRD3HTR2CADRB1HTR1A
Lysergide SCHEMBL30949883 1.00 HTR2A (1.00) HTR2ADRD3HTR2CADRB1HTR1A
Lysergide SCHEMBL29349465 1.00 HTR2A (1.00) HTR2ADRD3HTR2CADRB1HTR1A
Lysergide SCHEMBL27221708 1.00 HTR2A (1.00) HTR2ADRD3HTR2CADRB1HTR1A
Lysergide SCHEMBL23741954 1.00 HTR2A (1.00) HTR2ADRD3HTR2CADRB1HTR1A
Lysergide SCHEMBL467940 1.00 HTR2A (1.00) HTR2ADRD3HTR2CADRB1HTR1A
Lysergide SCHEMBL113755 1.00 HTR2A (1.00) HTR2ADRD3HTR2CADRB1HTR1A
Lysergide SCHEMBL12401704 1.00 HTR2A (1.00) HTR2ADRD3HTR2CADRB1HTR1A
Lysergide SCHEMBL22774200 0.99 HTR2A (0.98) HTR2ADRD3HTR2CADRB1HTR1A
Lysergide SCHEMBL28855252 0.99 HTR2A (0.98) HTR2ADRD3HTR2CADRB1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220160737-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH TURTLE BEAR HOLDINGS LLC (US) 2022-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220160737-A1 TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH HTR1B, HTR6, BDNF HTR2A 11/4885DRD3 104/4885HTR2C 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback